Ameco Medical to commence clinical trials for PNT procedure's reimbursement approval

NewsGuard 100/100 Score

Sunridge International (OTC Bulletin Board: SNDZ), announced today that Ameco Medical is preparing to start the short term clinical trials needed for reimbursement approval.  

Ameco Medical Equipment L.L.C., Sunridge's exclusive distributor for several Middle Eastern countries, has invited Dr. Leo D. Bores, Sunridge's medical consultant, to attend the start of their clinical trials.  Dr. Bores would be traveling to multiple countries in the Middle East to work with key opinion leaders at some of the largest hospitals and clinics in the region.  The purpose of the study will be to achieve reimbursement approval for the PNT procedure throughout the area.  

Sunridge International's CEO, G. Richard Smith states, "We strive to have a close working relationship with our distributors so that we can assist them when needed in order to obtain success.  Once reimbursement is established, the tens of thousands of glaucoma sufferers can avail themselves of this non-invasive treatment."

Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International www.oi-pnt.com.

Source:

Sunridge International

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advanced neuroimaging reveals surprising link between glaucoma and Alzheimer's disease